Sensome, a spin-off from CNRS and Ecole polytechnique (France), is a medtech startup pioneering the connected medical device revolution with the world’s smallest biological tissue sensor.
Sensome develops a breakthrough remote monitoring technology that can turn invasive vascular medical devices into connected healthcare devices.
Sensome was founded in 2014 by Franz Bozsak. The company is headquartered in Massy, Ile-de-France, France.
Sensome developed a revolutionary sensor technology that turns invasive medical devices into connected healthcare devices. The company’s sensing technology combines impedance-based micro-sensors with machine learning algorithms to instantly identify biological tissues upon contact with an unequaled predictive reliability.
Sensome's first application is the Clotild® connected guidewire for the treatment of ischemic stroke. Sensome's sensor technology can be deployed in multiple other medical fields, such as interventional cardiology and oncology.
Sensome is backed by ASAHI INTECC, Kurma Partners, Idinvest Partners, BNP Paribas Développement, Paris-Saclay Seed Fund and others. The company raised $9M from a Series B round on Jan 13, 2020. This brings Sensome's total funding to $18.9M to date.